Tiziana Life Sciences has dosed the first three patients in a Phase 2a trial testing foralumab, a nasal spray antibody, for treating early-stage ALS. The Healey ALS MyMatch BANYAN trial will enroll 44 patients to evaluate safety, tolerability, and immune effects over 24 weeks. This study, co-funded by the ALS Association, aims to explore foralumab's impact on regulatory T cells and neuroinflammation, with results potentially advancing ALS treatment options. The trial is ongoing at multiple US centers and includes a community webinar on October 1 to discuss the science behind foralumab.
The ALS trial of nasal antibody foralumab by Tiziana Life Sciences is underway as of September 28, 2026. For readers following the health sector, here is Pluang's market snapshot as of Sep 28, 2026 19:53 WIB: out of 100 priced health-sector US stocks, 23 rose and 64 fell. Notable movers include Acadia Healthcare Company Inc (ACHC) at USD 27.57 with a 1-day change of -1.85%, AbCellera Biologics Inc (ABCL) at USD 12.47 with -1.81%, and Aurora Cannabis Inc (ACB) at USD 4.04 with -1.46%.
Grail's stock surged 55% in one week following a positive FDA advisory committee vote on its Galleri multi-cancer early detection test, which was deemed safe and beneficial. Analyst Kyle Mikson raised the price target from $80 to $150, reflecting str...
Akamai Technologies is evolving from a content delivery network provider to a leader in distributed cloud and AI infrastructure, highlighted by a landmark $11.6 billion deal with Anthropic. Its CIS segment grew 39% year-over-year in Q2 2026, with all...
Apple shares have risen over 33% in the past year, and a $1,000 investment today could be worth about $1,621 by 2031 in a base scenario, reflecting a 62% total return. The bull case projects the investment nearly doubling to $1,952, while the bear ca...
ElevenLabs introduced its new v4 and v4 Turbo speech models, featuring faster voice cloning with just 10 seconds of audio, improved expression control, and support for over 90 languages. The models reduce latency for smoother voice agent interactions...
IKE Tech LLC has launched IKE 2.0, a next-generation compliance platform designed to maintain accountability for regulated products throughout their lifecycle, from manufacture to point of use. Initially focused on the global nicotine market, the pla...
